IO Biotech Q3 net loss $21.7M, cash $165.5M; Phase 3 melanoma trial fully enrolled

IO Biotech, Inc.

2023-Q3 EPS reported -$1.66

Net loss $21.7M in Q3 2023 vs $15.7M Q3 2022; R&D expenses $17.7M (up from $10.0M) driven by Phase 3 trial.
Cash and equivalents $165.5M at Sept 30, 2023, including $75M private placement; cash runway into Q4 2025.
Completed enrollment of 380 patients in pivotal Phase 3 (IO102-IO103 + pembrolizumab) for advanced melanoma; interim ORR expected Q3 2024, PFS H2 2025.
Appointed Helen Collins, MD to board; she serves as Chair of R&D Committee and brings extensive oncology drug development experience.
Presented encouraging preliminary Phase 2 data at WCLC and ESMO; three non-clinical posters at SITC 2023.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Helen Collins

Class II Director

IOBTQ · IO Biotech, Inc.

Effective: 2023-11-09
Filed: November 13, 2023, 6:59 PM ET

On November 9, 2023, the Company increased the size of the Board from seven to eight directors, and appointed Helen Collins, M.D. as a Class II director of the Company to fill the vacancy, effective as of that same date.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IO Biotech, Inc. reported the quarter ended September 30, 2023 results: net income $21.7 million.

Period: the quarter ended September 30, 2023
Net income: $21.7 million
Result: reported results

Exact text from the filing

Net loss for the three months ended September 30, 2023, was $21.7 million, compared to $15.7 million for the three months ended September 30, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Helen Collins was appointed as Class II Director at IO Biotech, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On November 9, 2023, the Company increased the size of the Board from seven to eight directors, and appointed Helen Collins, M.D. as a Class II director of the Company to fill the vacancy, effective as of that same date.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-275395

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.